Cargando…
IL-6 and IL-8 Serum Levels Predict Tumor Response and Overall Survival after TACE for Primary and Secondary Hepatic Malignancies
While surgical resection represents the standard potentially curative therapy for liver cancer, transarterial chemoembolization (TACE) has evolved as a standard therapy for intermediate-stage hepatocellular carcinoma (HCC) as well as liver metastases. However, it is still not fully understood which...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032291/ https://www.ncbi.nlm.nih.gov/pubmed/29899223 http://dx.doi.org/10.3390/ijms19061766 |
_version_ | 1783337479487619072 |
---|---|
author | Loosen, Sven H. Schulze-Hagen, Maximilian Leyh, Catherine Benz, Fabian Vucur, Mihael Kuhl, Christiane Trautwein, Christian Tacke, Frank Bruners, Philipp Roderburg, Christoph Luedde, Tom |
author_facet | Loosen, Sven H. Schulze-Hagen, Maximilian Leyh, Catherine Benz, Fabian Vucur, Mihael Kuhl, Christiane Trautwein, Christian Tacke, Frank Bruners, Philipp Roderburg, Christoph Luedde, Tom |
author_sort | Loosen, Sven H. |
collection | PubMed |
description | While surgical resection represents the standard potentially curative therapy for liver cancer, transarterial chemoembolization (TACE) has evolved as a standard therapy for intermediate-stage hepatocellular carcinoma (HCC) as well as liver metastases. However, it is still not fully understood which patients particularly benefit from TACE. Cytokines represent a broad category of signaling molecules that might reflect concomitant inflammation as an adverse prognostic factor. Here, we evaluated the role of interleukin (IL)-6, IL-8, and CC-chemokine ligand (CCL)22 as biomarkers in the context of TACE treatment. Cytokine serum levels were analyzed by multiplex immunoassay in 54 patients (HCC: n = 44, liver metastases: n = 10) undergoing TACE as well as 51 healthy controls. Patients with primary and secondary liver cancer showed significantly elevated levels of IL-6 and IL-8 but not CCL22 compared to healthy controls. Interestingly, low pre-interventional levels of IL-6 and IL-8 were predictors for an objective response after TACE in binary logistic regression. In contrast, patients with high pre-interventional IL-6 and IL-8 serum levels not only poorly responded to TACE but had a significantly impaired overall survival. Serum levels of IL-6 and IL-8 represent promising biomarkers for patients undergoing TACE and might help to pre-interventionally identify patients who particularly benefit from TACE regarding objective treatment response and overall survival. |
format | Online Article Text |
id | pubmed-6032291 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-60322912018-07-13 IL-6 and IL-8 Serum Levels Predict Tumor Response and Overall Survival after TACE for Primary and Secondary Hepatic Malignancies Loosen, Sven H. Schulze-Hagen, Maximilian Leyh, Catherine Benz, Fabian Vucur, Mihael Kuhl, Christiane Trautwein, Christian Tacke, Frank Bruners, Philipp Roderburg, Christoph Luedde, Tom Int J Mol Sci Article While surgical resection represents the standard potentially curative therapy for liver cancer, transarterial chemoembolization (TACE) has evolved as a standard therapy for intermediate-stage hepatocellular carcinoma (HCC) as well as liver metastases. However, it is still not fully understood which patients particularly benefit from TACE. Cytokines represent a broad category of signaling molecules that might reflect concomitant inflammation as an adverse prognostic factor. Here, we evaluated the role of interleukin (IL)-6, IL-8, and CC-chemokine ligand (CCL)22 as biomarkers in the context of TACE treatment. Cytokine serum levels were analyzed by multiplex immunoassay in 54 patients (HCC: n = 44, liver metastases: n = 10) undergoing TACE as well as 51 healthy controls. Patients with primary and secondary liver cancer showed significantly elevated levels of IL-6 and IL-8 but not CCL22 compared to healthy controls. Interestingly, low pre-interventional levels of IL-6 and IL-8 were predictors for an objective response after TACE in binary logistic regression. In contrast, patients with high pre-interventional IL-6 and IL-8 serum levels not only poorly responded to TACE but had a significantly impaired overall survival. Serum levels of IL-6 and IL-8 represent promising biomarkers for patients undergoing TACE and might help to pre-interventionally identify patients who particularly benefit from TACE regarding objective treatment response and overall survival. MDPI 2018-06-14 /pmc/articles/PMC6032291/ /pubmed/29899223 http://dx.doi.org/10.3390/ijms19061766 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Loosen, Sven H. Schulze-Hagen, Maximilian Leyh, Catherine Benz, Fabian Vucur, Mihael Kuhl, Christiane Trautwein, Christian Tacke, Frank Bruners, Philipp Roderburg, Christoph Luedde, Tom IL-6 and IL-8 Serum Levels Predict Tumor Response and Overall Survival after TACE for Primary and Secondary Hepatic Malignancies |
title | IL-6 and IL-8 Serum Levels Predict Tumor Response and Overall Survival after TACE for Primary and Secondary Hepatic Malignancies |
title_full | IL-6 and IL-8 Serum Levels Predict Tumor Response and Overall Survival after TACE for Primary and Secondary Hepatic Malignancies |
title_fullStr | IL-6 and IL-8 Serum Levels Predict Tumor Response and Overall Survival after TACE for Primary and Secondary Hepatic Malignancies |
title_full_unstemmed | IL-6 and IL-8 Serum Levels Predict Tumor Response and Overall Survival after TACE for Primary and Secondary Hepatic Malignancies |
title_short | IL-6 and IL-8 Serum Levels Predict Tumor Response and Overall Survival after TACE for Primary and Secondary Hepatic Malignancies |
title_sort | il-6 and il-8 serum levels predict tumor response and overall survival after tace for primary and secondary hepatic malignancies |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032291/ https://www.ncbi.nlm.nih.gov/pubmed/29899223 http://dx.doi.org/10.3390/ijms19061766 |
work_keys_str_mv | AT loosensvenh il6andil8serumlevelspredicttumorresponseandoverallsurvivalaftertaceforprimaryandsecondaryhepaticmalignancies AT schulzehagenmaximilian il6andil8serumlevelspredicttumorresponseandoverallsurvivalaftertaceforprimaryandsecondaryhepaticmalignancies AT leyhcatherine il6andil8serumlevelspredicttumorresponseandoverallsurvivalaftertaceforprimaryandsecondaryhepaticmalignancies AT benzfabian il6andil8serumlevelspredicttumorresponseandoverallsurvivalaftertaceforprimaryandsecondaryhepaticmalignancies AT vucurmihael il6andil8serumlevelspredicttumorresponseandoverallsurvivalaftertaceforprimaryandsecondaryhepaticmalignancies AT kuhlchristiane il6andil8serumlevelspredicttumorresponseandoverallsurvivalaftertaceforprimaryandsecondaryhepaticmalignancies AT trautweinchristian il6andil8serumlevelspredicttumorresponseandoverallsurvivalaftertaceforprimaryandsecondaryhepaticmalignancies AT tackefrank il6andil8serumlevelspredicttumorresponseandoverallsurvivalaftertaceforprimaryandsecondaryhepaticmalignancies AT brunersphilipp il6andil8serumlevelspredicttumorresponseandoverallsurvivalaftertaceforprimaryandsecondaryhepaticmalignancies AT roderburgchristoph il6andil8serumlevelspredicttumorresponseandoverallsurvivalaftertaceforprimaryandsecondaryhepaticmalignancies AT lueddetom il6andil8serumlevelspredicttumorresponseandoverallsurvivalaftertaceforprimaryandsecondaryhepaticmalignancies |